2-Benzylsuccinic acid
Based on 1 publication(s) in Google Scholar
2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis.
For research use only. We do not sell to patients.
- Purity: 99.83%
- CAS No.: 884-33-3
- Formula: C11H12O4
- Molecular Weight:208.21
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) 2-Benzylsuccinic acid
More
Biological Activity
2-Benzylsuccinic acid (5-10 mM) reduces the activity of Nna1 (a cytosolic carboxypeptidase) when biotin-3EG2E is used as a substrate, with an inhibition rate of approximately 95% at 10 mM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 884-33-3
-
Appearance Solid
-
Molecular Weight 208.21
-
Formula C11H12O4
-
Color White to off-white
-
SMILES
O=C(O)C(CC1=CC=CC=C1)CC(O)=O
-
Synonyms
DL-Benzylsuccinic acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Mol Gastroenterol Hepatol
Mast Cells Inhibit Stem Cell-driven Epithelial Repair in Inflammatory Bowel Disease via Suppressing Wnt/lrp6/β-Catenin Signaling Pathway. [Abstract]2026;20(5):101741. PMID: 41616821
Solvent & Solubility
DMSO : 500 mg/mL (2401.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 4.17 mg/mL (20.03 mM); Clear solution
This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 4.17 mg/mL (20.03 mM); Clear solution
This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Han MS, et al. A novel strategy for designing irreversible inhibitors of metalloproteases: acetals as latent electrophiles that interact with catalytic nucleophile at the active site. Org Lett. 2000 Oct 5;2(20):3149-52. [Content Brief]
[2]. Wang R, et al. Identification of 2-PMPA as a novel inhibitor of cytosolic carboxypeptidases. Biochem Biophys Res Commun. 2020 Dec 17;533(4):1393-1399. [Content Brief]
[3]. Duan J, et al. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. Hepatology. 2022 Jan;75(1):140-153. [Content Brief]
[4]. Kühlein HN, et al. Nerve injury evoked loss of latexin expression in spinal cord neurons contributes to the development of neuropathic pain. PLoS One. 2011 Apr 29;6(4):e19270. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.8028 mL | 24.0142 mL | 48.0284 mL | 120.0711 mL |
| 5 mM | 0.9606 mL | 4.8028 mL | 9.6057 mL | 24.0142 mL | |
| 10 mM | 0.4803 mL | 2.4014 mL | 4.8028 mL | 12.0071 mL | |
| 15 mM | 0.3202 mL | 1.6009 mL | 3.2019 mL | 8.0047 mL | |
| 20 mM | 0.2401 mL | 1.2007 mL | 2.4014 mL | 6.0036 mL | |
| 25 mM | 0.1921 mL | 0.9606 mL | 1.9211 mL | 4.8028 mL | |
| 30 mM | 0.1601 mL | 0.8005 mL | 1.6009 mL | 4.0024 mL | |
| 40 mM | 0.1201 mL | 0.6004 mL | 1.2007 mL | 3.0018 mL | |
| 50 mM | 0.0961 mL | 0.4803 mL | 0.9606 mL | 2.4014 mL | |
| 60 mM | 0.0800 mL | 0.4002 mL | 0.8005 mL | 2.0012 mL | |
| 80 mM | 0.0600 mL | 0.3002 mL | 0.6004 mL | 1.5009 mL | |
| 100 mM | 0.0480 mL | 0.2401 mL | 0.4803 mL | 1.2007 mL |